Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention

Heart and Lung: Journal of Acute and Critical Care

Volumn 36, Issue 3, 2007, Pages 195-204

  Seyon, Rajamalar A ^a,b   Jensen, Louise A ^b   Ferguson, Ian A ^a   Williams, Randall G ^a,b  

^a ROYAL ALEXANDRA HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CONTRAST MEDIUM; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IODIXANOL; IOHEXOL; METOLAZONE; PLACEBO; ROFECOXIB; SPIRONOLACTONE;

ACUTE CORONARY SYNDROME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYDRATION; KIDNEY DISEASE; KIDNEY FAILURE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACETYLCYSTEINE; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; FLUID THERAPY; FREE RADICAL SCAVENGERS; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; PLACEBOS; RENAL INSUFFICIENCY, ACUTE; RISK FACTORS; SODIUM CHLORIDE;

EID: 34248193726     PISSN: 01479563     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2006.08.004     Document Type: Article

References (41)

1. American Heart Association. 2002 Heart and stroke statistical update (2001), American Heart Association, Dallas, TX
2. Scanlon P.J., Faxon D.P., Audet A.M., et al. ACC/AHA guidelines for coronary angiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography). J Am Coll Cardiol 33 (1999) 1756-1824
3. Spinler S.A., and Goldfarb S. Nephrotoxicity of contrast media following cardiac angiography: pathogenesis, clinical course, and preventive measures, including the role of low-osmolality contrast media. Ann Pharmacother 26 1 (1992) 56-64
4. Deray G., and Jacobs C. Radiocontrast nephrotoxicity: a review. Invest Radiol 30 4 (1995) 221-225
5. Morcos S.K., Thomsen H.S., Webb J.A.W., and Contrast Media Safety Committee of the European Society of Urogenital Radiology. Contrast-media-induced nephrotoxicity: a consensus report. Eur Radiol 9 (1999) 1602-1613
6. Quader M.A., Sawmiller C., and Sumpio B.A. Contrast-induced nephropathy: review of incidence and pathophysiology. Ann Vasc Surg 12 6 (1998) 612-620
7. Tommaso C.L. Contrast-induced nephrotoxicity in patients undergoing cardiac catheterization. Cathet Cardiovasc Diagn 31 (1994) 316-321
8. Davidson C.J., Hlatky M., Morris K.G., et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. Ann Intern Med 110 2 (1989) 119-124
9. Taliercio C.P., McCallister S.H., Holmes Jr. D.R., Ilstrup D.M., and Vlietstra R.E. Nephrotoxicity of non-ionic contrast media after cardiac angiography. Am J Cardiol 64 12 (1989) 815-816
10. Abizaid A.S., Clark C.E., Mintz G.S., et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with pre-existing renal insufficiency. Am J Cardiol 83 (1999) 260-263
11. Martin-Paredero V., Dixon S.M., Baker J.D., et al. Risk of renal failure after major angiography. Arch Surg 118 (1983) 1417-1420
12. McCullough P.A., Wolyn R., Rocher L.L., Levin R.N., and O'Neill W.W. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103 (1997) 368-375
13. Parfrey P.S., Griffiths S.M., Barrett B.J., et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 320 3 (1989) 143-149
14. Schwab S.J., Hlatky M.A., Pieper K.S., et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 320 3 (1989) 149-153
15. Solomon R., Werner C., Mann D., D'Elia J., and Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331 21 (1994) 1416-1420
16. Stevens M.A., McCullough P.A., Tobin K.J., et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. J Am Coll Cardiol 33 2 (1999) 403-411
17. Taliercio C.P., Vlietstra R.E., Ilstrup D.M., et al. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol 17 2 (1991) 384-390
18. Tepel M., Van Der Giet M., Schwarzfeld C., Laufer U., Liermann D., and Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343 3 (2000) 180-184
19. Murphy S.W., Barrett B.J., and Parfrey P.S. Contrast nephropathy. J Am Soc Nephrol 11 1 (2000) 177-182
20. Baker C.S.R., Wragg A., Kumar S., De Palma R., Baker L.R.I., and Knight C.J. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 41 12 (2003) 2114-2118
21. Boccalandro F., Amhad M., Smalling R.W., and Sdringola S. Oral N-acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 58 (2003) 336-341
22. Kay J., Chow W.H., Chan T.M., et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 289 5 (2003) 553-557
23. Tadros G.M., Mouhayar E.N., Akinwande A.O., et al. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invasive Cardiol 15 6 (2003) 311-314
24. Oldemeyer J.B., Biddle W.P., Wurdeman R.L., Mooss A.N., Cichowski E., and Hilleman D.E. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 146 6 (2003) 23-28
25. Adamian M.G., Moussa I., Mehran R., et al. The role of Mucomyst administration prior to percutaneous interventions on renal function in patients with chronic renal failure. J Am Coll Cardiol 39 Suppl-March (2002) 1A Abstract No. 1004.I-10
26. Diaz-Sandoval L.J., Kosowsky B.D., and Losordo D.W. Acetylcysteine to prevent angiography-related renal tissue injury (The APART Trail). Am J Cardiol 89 3 (2002) 356-358
27. Durrham J.D., Caputo C., Dokko J., et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 62 (2002) 2202-2207
28. Shyu K., Cheng J., and Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 40 8 (2002) 1383-1388
29. Briguori C., Manganelli F., Scarpato P., et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 40 2 (2002) 298-303
30. Vellero A., Cesano G., Pozzato M., et al. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine]. Giornale Italiano di Nefrologia 19 5 (2002) 529-533
31. Birck R., Krzossok S., Markowetz F., Schnülle P., van der Woude F.J., and Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 362 (2003) 598-603
32. Isenbarger D.W., Kent S.M., and O'Malley P.G. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 92 (2003) 1454-1458
33. Bailey S.R. Past and present attempts to prevent radiocontrast nephropathy. Rev Cardiovasc Med 2 Suppl 1 (2001) S14-S18
34. Gruberg L., Mintz G.S., Mehran R., et al. The prognostic implications of further renal function deterioration within 48 hours of interventional coronary procedures in patients with pre-existing chronic renal insufficiency. J Am Coll Cardiol 36 5 (2000) 1542-1548
35. Huber W., Jeschke B., Kreymann B., et al. Haemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. Invest Radiol 37 9 (2002) 471-481
36. McCullough P.A. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes?. J Am Coll Cardiol 41 5 (2003) 725-728
37. Mann J.F.E., Gerstein H.C., Pogue J., Bosch J., and Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134 8 (2001) 629-636
38. Marenzi G., Bartorelli A.L., Lauri G., et al. Continuous veno-venous hemofiltration for the treatment of contrast-induced acute renal failure after percutaneous coronary interventions. Catheter Cardiovasc Interv 58 (2003) 59-64
39. Marenzi G., Marana I., Lauri G., et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 349 14 (2003) 1333-1340
40. Nikolsky E., and Mehran R. Understanding the consequences of contrast-induced nephropathy. Rev Cardiovasc Med 4 Suppl 5 (2003) S10-S18
41. Vogt B., Ferrari P., Schonholzer C., et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 11 (2001) 692-698